GT 1, 4, 5, 6 | GT 2 and 3 | ||||||
NEUTRINO | FISSION | POSITRON | FUSION | ||||
SOF/PEG/RBV (n = 327) | SOF/RBV (n = 253) | PEG/RBV (n = 243) | SOF/RBV (n = 207) | Placebo (n = 71) | SOF/RBV 12 week (n = 100) | SOF/RBV 16 week (n = 95) | |
Overall | 91% | 67% | 67% | 78% | 0% | 50% | 73% |
GT 2 | N/A | 97% | 78% | 93% | 0% | 86% | 94% |
GT 3 | N/A | 56% | 63% | 61% | 0% | 30% | 62% |
Noncirrhotic | 93% | 72% | 74% | 81% | 0% | 61% | 76% |
Cirrhotic | 80% | 47% | 38% | 61% | 0% | 31% | 66% |